S-Ethylisothiourea is a nitric oxide synthase inhibitor.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Buprenorphine | S-Ethylisothiourea may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
| Doxylamine | Doxylamine may increase the central nervous system depressant (CNS depressant) activities of S-Ethylisothiourea. |
| Dronabinol | Dronabinol may increase the central nervous system depressant (CNS depressant) activities of S-Ethylisothiourea. |
| Droperidol | Droperidol may increase the central nervous system depressant (CNS depressant) activities of S-Ethylisothiourea. |
| Hydrocodone | S-Ethylisothiourea may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone. |
| Hydroxyzine | Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of S-Ethylisothiourea. |
| Magnesium sulfate | The therapeutic efficacy of S-Ethylisothiourea can be increased when used in combination with Magnesium sulfate. |
| Methotrimeprazine | S-Ethylisothiourea may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. |
| Metyrosine | S-Ethylisothiourea may increase the sedative activities of Metyrosine. |
| Minocycline | Minocycline may increase the central nervous system depressant (CNS depressant) activities of S-Ethylisothiourea. |
| Mirtazapine | S-Ethylisothiourea may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine. |
| Nabilone | Nabilone may increase the central nervous system depressant (CNS depressant) activities of S-Ethylisothiourea. |
| Orphenadrine | S-Ethylisothiourea may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. |
| Paraldehyde | S-Ethylisothiourea may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. |
| Perampanel | Perampanel may increase the central nervous system depressant (CNS depressant) activities of S-Ethylisothiourea. |
| Pramipexole | S-Ethylisothiourea may increase the sedative activities of Pramipexole. |
| Ropinirole | S-Ethylisothiourea may increase the sedative activities of Ropinirole. |
| Rotigotine | S-Ethylisothiourea may increase the sedative activities of Rotigotine. |
| Rufinamide | The risk or severity of adverse effects can be increased when Rufinamide is combined with S-Ethylisothiourea. |
| Suvorexant | S-Ethylisothiourea may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. |
| Tapentadol | Tapentadol may increase the central nervous system depressant (CNS depressant) activities of S-Ethylisothiourea. |
| Thalidomide | S-Ethylisothiourea may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. |
| Zolpidem | S-Ethylisothiourea may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. |
| Methadone | The risk or severity of adverse effects can be increased when Methadone is combined with S-Ethylisothiourea. |
| Sodium oxybate | S-Ethylisothiourea may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate. |
| Ethanol | S-Ethylisothiourea may increase the central nervous system depressant (CNS depressant) activities of Ethanol. |
| Azelastine | S-Ethylisothiourea may increase the central nervous system depressant (CNS depressant) activities of Azelastine. |
| Brimonidine | Brimonidine may increase the central nervous system depressant (CNS depressant) activities of S-Ethylisothiourea. |
| Fluvoxamine | The risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Fluvoxamine. |
| Citalopram | The risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Citalopram. |
| Duloxetine | The risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Duloxetine. |
| Trazodone | The risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Trazodone. |
| Paroxetine | The risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Paroxetine. |
| Sertraline | The risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Sertraline. |
| Sibutramine | The risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Sibutramine. |
| Nefazodone | The risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Nefazodone. |
| Escitalopram | The risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Escitalopram. |
| Zimelidine | The risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Zimelidine. |
| Dapoxetine | The risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Dapoxetine. |
| Milnacipran | The risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Milnacipran. |
| Desvenlafaxine | The risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Desvenlafaxine. |
| Seproxetine | The risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Seproxetine. |
| Indalpine | The risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Indalpine. |
| Ritanserin | The risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Ritanserin. |
| Alaproclate | The risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Alaproclate. |
| Amitriptyline | The risk or severity of CNS depression can be increased when Amitriptyline is combined with S-Ethylisothiourea. |
| Cyproheptadine | The risk or severity of CNS depression can be increased when Cyproheptadine is combined with S-Ethylisothiourea. |
| Imipramine | The risk or severity of CNS depression can be increased when Imipramine is combined with S-Ethylisothiourea. |
| Nortriptyline | The risk or severity of CNS depression can be increased when Nortriptyline is combined with S-Ethylisothiourea. |
| Amoxapine | The risk or severity of CNS depression can be increased when Amoxapine is combined with S-Ethylisothiourea. |
| Propiomazine | The risk or severity of CNS depression can be increased when Propiomazine is combined with S-Ethylisothiourea. |
| Maprotiline | The risk or severity of CNS depression can be increased when Maprotiline is combined with S-Ethylisothiourea. |
| Doxepin | The risk or severity of CNS depression can be increased when Doxepin is combined with S-Ethylisothiourea. |
| Desipramine | The risk or severity of CNS depression can be increased when Desipramine is combined with S-Ethylisothiourea. |
| Pizotifen | The risk or severity of CNS depression can be increased when S-Ethylisothiourea is combined with Pizotifen. |
| Dosulepin | The risk or severity of CNS depression can be increased when S-Ethylisothiourea is combined with Dosulepin. |
| Zopiclone | The risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Zopiclone. |
| Botulinum toxin type B | The risk or severity of CNS depression can be increased when Botulinum toxin type B is combined with S-Ethylisothiourea. |
| Botulinum toxin type A | The risk or severity of CNS depression can be increased when Botulinum toxin type A is combined with S-Ethylisothiourea. |
| Tryptophan | The risk or severity of CNS depression can be increased when Tryptophan is combined with S-Ethylisothiourea. |
| Baclofen | Baclofen may increase the central nervous system depressant (CNS depressant) activities of S-Ethylisothiourea. |
| Lorazepam | The risk or severity of CNS depression can be increased when Lorazepam is combined with S-Ethylisothiourea. |
| Ethchlorvynol | The risk or severity of CNS depression can be increased when Ethchlorvynol is combined with S-Ethylisothiourea. |
| Succinylcholine | The risk or severity of CNS depression can be increased when Succinylcholine is combined with S-Ethylisothiourea. |
| Reserpine | The risk or severity of CNS depression can be increased when Reserpine is combined with S-Ethylisothiourea. |
| Eletriptan | The risk or severity of CNS depression can be increased when Eletriptan is combined with S-Ethylisothiourea. |
| Enflurane | The risk or severity of CNS depression can be increased when Enflurane is combined with S-Ethylisothiourea. |
| Temazepam | The risk or severity of CNS depression can be increased when Temazepam is combined with S-Ethylisothiourea. |
| Reboxetine | The risk or severity of CNS depression can be increased when Reboxetine is combined with S-Ethylisothiourea. |
| Butabarbital | The risk or severity of CNS depression can be increased when Butabarbital is combined with S-Ethylisothiourea. |
| Butalbital | The risk or severity of CNS depression can be increased when Butalbital is combined with S-Ethylisothiourea. |
| Methysergide | The risk or severity of CNS depression can be increased when Methysergide is combined with S-Ethylisothiourea. |
| Cabergoline | The risk or severity of CNS depression can be increased when Cabergoline is combined with S-Ethylisothiourea. |
| Phenytoin | The risk or severity of CNS depression can be increased when Phenytoin is combined with S-Ethylisothiourea. |
| Topiramate | The risk or severity of CNS depression can be increased when Topiramate is combined with S-Ethylisothiourea. |
| Clemastine | The risk or severity of CNS depression can be increased when Clemastine is combined with S-Ethylisothiourea. |
| Venlafaxine | The risk or severity of CNS depression can be increased when Venlafaxine is combined with S-Ethylisothiourea. |
| Etomidate | The risk or severity of CNS depression can be increased when Etomidate is combined with S-Ethylisothiourea. |
| Morphine | The risk or severity of CNS depression can be increased when Morphine is combined with S-Ethylisothiourea. |
| Talbutal | The risk or severity of CNS depression can be increased when Talbutal is combined with S-Ethylisothiourea. |
| Pentobarbital | The risk or severity of CNS depression can be increased when Pentobarbital is combined with S-Ethylisothiourea. |
| Valproic acid | The risk or severity of CNS depression can be increased when Valproic acid is combined with S-Ethylisothiourea. |
| Zolmitriptan | The risk or severity of CNS depression can be increased when Zolmitriptan is combined with S-Ethylisothiourea. |
| Codeine | The risk or severity of CNS depression can be increased when Codeine is combined with S-Ethylisothiourea. |
| Dihydroergotamine | The risk or severity of CNS depression can be increased when Dihydroergotamine is combined with S-Ethylisothiourea. |
| Tolcapone | The risk or severity of CNS depression can be increased when Tolcapone is combined with S-Ethylisothiourea. |
| Hydromorphone | The risk or severity of CNS depression can be increased when Hydromorphone is combined with S-Ethylisothiourea. |
| Olanzapine | The risk or severity of CNS depression can be increased when Olanzapine is combined with S-Ethylisothiourea. |
| Cetirizine | The risk or severity of CNS depression can be increased when Cetirizine is combined with S-Ethylisothiourea. |
| Protriptyline | The risk or severity of CNS depression can be increased when Protriptyline is combined with S-Ethylisothiourea. |
| Trimethadione | The risk or severity of CNS depression can be increased when Trimethadione is combined with S-Ethylisothiourea. |
| Clobazam | The risk or severity of sedation, somnolence, and CNS depression can be increased when Clobazam is combined with S-Ethylisothiourea. |
| Chlorzoxazone | The risk or severity of CNS depression can be increased when Chlorzoxazone is combined with S-Ethylisothiourea. |
| Clozapine | The risk or severity of CNS depression can be increased when Clozapine is combined with S-Ethylisothiourea. |
| Meprobamate | The risk or severity of CNS depression can be increased when Meprobamate is combined with S-Ethylisothiourea. |
| Thiethylperazine | The risk or severity of CNS depression can be increased when Thiethylperazine is combined with S-Ethylisothiourea. |
| Palonosetron | The risk or severity of CNS depression can be increased when Palonosetron is combined with S-Ethylisothiourea. |
| Sulpiride | The risk or severity of CNS depression can be increased when Sulpiride is combined with S-Ethylisothiourea. |
| Alprazolam | The risk or severity of CNS depression can be increased when Alprazolam is combined with S-Ethylisothiourea. |
| Dexbrompheniramine | The risk or severity of CNS depression can be increased when Dexbrompheniramine is combined with S-Ethylisothiourea. |